About esperion therapeutics - ESPR
Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
ESPR At a Glance
Esperion Therapeutics, Inc.
3891 Ranchero Drive
Ann Arbor, Michigan 48108
| Phone | 1-734-887-3903 | Revenue | 403.14M | |
| Industry | Pharmaceuticals: Major | Net Income | -22,682,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 21.311% | |
| Fiscal Year-end | 12 / 2026 | Employees | 294 | |
| View SEC Filings |
ESPR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.908 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 19.034 |
| Enterprise Value to Sales | 2.851 |
| Total Debt to Enterprise Value | 0.477 |
ESPR Efficiency
| Revenue/Employee | 1,371,207.483 |
| Income Per Employee | -77,149.66 |
| Receivables Turnover | 2.876 |
| Total Asset Turnover | 0.656 |
ESPR Liquidity
| Current Ratio | 1.538 |
| Quick Ratio | 1.188 |
| Cash Ratio | 0.558 |
ESPR Profitability
| Gross Margin | 67.945 |
| Operating Margin | 14.951 |
| Pretax Margin | -5.17 |
| Net Margin | -5.626 |
| Return on Assets | -3.691 |
| Return on Equity | N/A |
| Return on Total Capital | -9.219 |
| Return on Invested Capital | -17.865 |
ESPR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 222.733 |
| Total Debt to Total Assets | 62.009 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 186.275 |